Voyager Therapeut (VYGR)

May 6, 2025, 4:01 PM EDT - 8 days ago

Voyager Reports First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 4:30 PM EDT - 16 days ago

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Mar 31, 2025, 7:00 AM EDT - 6 weeks ago

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Mar 11, 2025, 7:35 PM EDT - 2 months ago

Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:01 PM EDT - 2 months ago

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 4, 2025, 7:00 AM EST - 2 months ago

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

Mar 3, 2025, 7:00 AM EST - 2 months ago

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease

Mar 2, 2025, 11:00 AM EST - 2 months ago

The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation

Feb 25, 2025, 7:00 AM EST - 2 months ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Feb 21, 2025, 10:51 PM EST - 2 months ago

VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 11, 2025, 7:00 AM EST - 3 months ago

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Jan 30, 2025, 5:06 PM EST - 3 months ago

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

Nov 12, 2024, 11:07 PM EST - 6 months ago

Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 6 months ago

Voyager Reports Third Quarter 2024 Financial and Operating Results

Nov 5, 2024, 7:00 AM EST - 6 months ago

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Aug 29, 2024, 4:01 PM EDT - 9 months ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 26, 2024, 3:24 PM EDT - 9 months ago

Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects

Aug 8, 2024, 5:43 AM EDT - 10 months ago

Voyager Therapeutics, Inc. (VYGR) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 10 months ago

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 6, 2024, 4:01 PM EDT - 10 months ago

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Jun 13, 2024, 4:01 PM EDT - 11 months ago

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

Jun 7, 2024, 6:26 PM EDT - 1 year ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV CRSP ENVX GAM HAL LPA

Jun 5, 2024, 11:52 AM EDT - 1 year ago

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 2, 2024, 10:18 AM EDT - 1 year ago

3 Biotech Names Under $10 I Own

AUPH FOLD

May 16, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease

May 14, 2024, 4:43 AM EDT - 1 year ago

Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:01 PM EDT - 1 year ago

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

May 8, 2024, 6:00 AM EDT - 1 year ago

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

May 6, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Mar 13, 2024, 1:11 PM EDT - 1 year ago

Voyager Therapeutics: On Track To Deliver High Returns On Investment

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

Mar 8, 2024, 3:25 PM EST - 1 year ago

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier